NCT01855737

The Study of Warfarin Maintenance Dose in Chinese Patients

Clinical Study of the Relationship Between Pharmacogenomics and Warfarin Dose in Chinese Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

1. Title: Clinical study of the relationship between Pharmacogenomics and warfarin dose in Chinese patients 2. Drug: Warfarin 3. Design: To value the accuracy of warfarin Pharmacogenomics algorithm by the algorithm calculated dose and actual dose in the Chinese patients. 4. Hypothesis:Pharmacogenomic algorithm guided dose can help to predict warfarin dose in Chinese patients.

Detailed description

* For the patients who need to use warfarin, detect the "Vitamin K epoxide reductase complex subunit 1 (VKORC1),cytochrome p450 2C9 (CYP2C9), and cytochrome p450 4F2 (CYP4F2) genotype. * Record the demographic information: gender, age, height, and weight. * Record drug combination, complications, and international normalized ratio (INR), liver function and kidney function or other biochemical test results. * Put genotypes, demographic information and other clinical information into the algorithm to calculate warfarin dose for the patients, and compared with the actual dose.

Conditions

• Atrial Fibrillation
• Heart Valve Disease
• Pulmonary Artery Embolism

Interventions

Type	Name	Description
DRUG	Warfarin	Prescribe warfarin to the patients who are needed.

Timeline

• Start date: 2013-06-01
• Primary completion: 2013-12-01
• Completion: 2014-01-01
• First posted: 2013-05-16
• Last updated: 2013-06-04

Locations

1 site across 1 country: China